Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer
Status:
Completed
Trial end date:
2018-10-05
Target enrollment:
Participant gender:
Summary
Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is
overexpressed manifold on prostate cancer cells and is well-characterized as an imaging
biomarker of prostate cancer. Positron emission tomography / computer tomography (PET/CT) is
a nuclear medicine procedure based on the measurement of positron emission from radiolabeled
tracer molecules. 18F-DCFPyL is a tracer for prostate cancer PET imaging which binds to PSMA.
The strength of functional imaging methods is in distinguishing tissues according to
metabolism rather than structure. Studies have shown that PET/CT imaging with 18F-DCFPyL can
detect prostate cancer lesions with excellent contrast and a high detection rate even when
the level of prostate specific antigen is low.
The objective of this study is to evaluate if the patient-wide SUVmax on 18F-DCFPyL PET/CT in
locoregional and metastatic prostate cancer correlates with histopathologic Gleason score at
initial biopsy. It is hypothesized that SUVmax will correlate positively with Gleason score.
This is of interest because non-invasive risk stratification may be possible in the future.